Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Drug Biotransformation: Overview01:16

Drug Biotransformation: Overview

2.4K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.4K
Drug Absorption: Overview01:17

Drug Absorption: Overview

572
The process of drug absorption signifies the transition of a drug from its site of administration into the plasma. This process is influenced by various factors, including the route of administration, the anatomy of the absorption site, the mechanism of absorption, gut motility, and the drug's physicochemical properties.
When drugs are injected intravenously, they directly enter the systemic circulation. Alternatively, orally administered drugs navigate through the gastrointestinal (GI)...
572
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

316
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
316
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

157
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
157
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

155
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
155
Biopharmaceutics and Pharmacokinetics: Overview01:28

Biopharmaceutics and Pharmacokinetics: Overview

2.0K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
2.0K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Pseudomonal sternal abscess and osteomyelitis as an initial manifestation of common variable immunodeficiency.

ASM case reports·2026
Same author

Distinct molecular epidemiology and outcomes of carbapenem-resistant gram-negative infections in Lebanon: insights from the MDRO network.

BMC infectious diseases·2026
Same author

Association Between Cirrhosis and Acute or Severe Limb Ischemic Events Among Hospitalizations with Peripheral Artery Disease: A National Inpatient Sample Analysis.

Medicina (Kaunas, Lithuania)·2026
Same author

Life-threatening neurotoxicity following off-label ivermectin use in metastatic breast cancer: a case report.

Postgraduate medicine·2026
Same author

Meeting the 2024 UN General Assembly declaration targets on antimicrobial resistance.

Lancet (London, England)·2026
Same author

Efficacy and Safety of Diaphragmatic Breathing Exercises for Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis.

Journal of clinical medicine·2026

相关实验视频

Updated: Jun 24, 2025

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

8.3K

Ibrexafungerp:一个叙事概述

L'Emir Wassim El Ayoubi1, Fatima Allaw1, Elie Moussa2

  • 1Division of Infectious Diseases, American University of Beirut Medical Center, Beirut, Lebanon.

Current research in microbial sciences
|June 14, 2024
PubMed
概括
此摘要是机器生成的。

伊布雷克萨格尔普 (IBX) 是一种新型抗真菌药物,可以抑制真菌细胞壁的合成. 它在抗性菌株和临床试验中显示出对各种感染的有效性,包括 vulvovaginal candidiasis.

关键词:
它们是Candida auris.在Ibrexafungerpp中使用侵袭性角膜炎症是一种侵袭性疾病.侵袭性肺部阿斯伯吉洛症 (Aspergillosis) 是一种侵袭性肺部阿斯伯吉洛症.Vulvovaginal 候选症的发生

更多相关视频

Author Spotlight: Investigating Islet Abnormalities and Function with a Pseudoislet Protocol
08:04

Author Spotlight: Investigating Islet Abnormalities and Function with a Pseudoislet Protocol

Published on: November 3, 2023

1.9K
Monitoring On-Target Signaling Responses in Larval Zebrafish - Z-REX Unmasks Precise Mechanisms of Electrophilic Drugs and Metabolites
05:28

Monitoring On-Target Signaling Responses in Larval Zebrafish - Z-REX Unmasks Precise Mechanisms of Electrophilic Drugs and Metabolites

Published on: June 2, 2023

800

相关实验视频

Last Updated: Jun 24, 2025

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

8.3K
Author Spotlight: Investigating Islet Abnormalities and Function with a Pseudoislet Protocol
08:04

Author Spotlight: Investigating Islet Abnormalities and Function with a Pseudoislet Protocol

Published on: November 3, 2023

1.9K
Monitoring On-Target Signaling Responses in Larval Zebrafish - Z-REX Unmasks Precise Mechanisms of Electrophilic Drugs and Metabolites
05:28

Monitoring On-Target Signaling Responses in Larval Zebrafish - Z-REX Unmasks Precise Mechanisms of Electrophilic Drugs and Metabolites

Published on: June 2, 2023

800

科学领域:

  • 菌类学 菌类学是指菌类学.
  • 药理学 药理学是指药理学的学科.
  • 传染性疾病 传染性疾病

背景情况:

  • 伊布雷克萨格尔普 (IBX) 是一种新的抗真菌剂,向真菌细胞壁合成.
  • 它抑制β-(1,3)-D-葡萄糖 (BDG) 合成酶,提供与现有的抗真菌药物不同的机制.
  • IBX对广泛的真菌病原体表现出活性,包括耐药菌株.

研究的目的:

  • 评估作为一种新型抗真菌剂的ibrexafungerp (IBX) 的疗效和安全性.
  • 评估IBX对各种真菌物种的活性,包括耐药菌株和临床前模型.
  • 审查IBX在治疗 кандидоз和阿斯伯吉洛症方面的临床试验数据.

主要方法:

  • 对IBX的作用机制,活性谱和药理动力学性质的临床前数据的审查.
  • 在体研究中对入侵性候群病 (IC) 和入侵性肺阿斯伯吉洛症 (IPA) 的小鼠模型进行分析.
  • 检查临床试验结果,检查 vulvovaginal candidasis (VVC),IC,以及新出现的病原体,如 *Candida auris*.

主要成果:

  • IBX表现出广泛的活性,包括对抗耐醇和耐氨菌株,并具有抗生物膜特性.
  • 药物动力学研究表明,具有良好的生物可用性和组织分布,药物相互作用潜力较低.
  • 临床试验表明IBX在VVC治疗和预防方面不低于可纳,在IC和*C. auris*感染方面取得了有希望的结果.

结论:

  • 伊布雷克萨格柏 (IBX) 是抗真菌疗法的重大进展,因为它具有独特的机制和广泛的活性.
  • 它在VVC临床试验中的有效性和对侵入性真菌感染的有希望的结果证明了它在抗真菌武器库中的地位.
  • 建议对IBX进行进一步的研究,特别是在复杂和耐火性真菌感染中.